BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35712255)

  • 1. Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response.
    Cristalli C; Manara MC; Valente S; Pellegrini E; Bavelloni A; De Feo A; Blalock W; Di Bello E; Piñeyro D; Merkel A; Esteller M; Tirado OM; Mai A; Scotlandi K
    Front Endocrinol (Lausanne); 2022; 13():876602. PubMed ID: 35712255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.
    Manara MC; Valente S; Cristalli C; Nicoletti G; Landuzzi L; Zwergel C; Mazzone R; Stazi G; Arimondo PB; Pasello M; Guerzoni C; Picci P; Nanni P; Lollini PL; Mai A; Scotlandi K
    Mol Cancer Ther; 2018 Sep; 17(9):1881-1892. PubMed ID: 29959201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
    Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
    PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.
    Huertas-Martínez J; Court F; Rello-Varona S; Herrero-Martín D; Almacellas-Rabaiget O; Sáinz-Jaspeado M; Garcia-Monclús S; Lagares-Tena L; Buj R; Hontecillas-Prieto L; Sastre A; Azorin D; Sanjuan X; López-Alemany R; Moran S; Roma J; Gallego S; Mora J; García Del Muro X; Giangrande PH; Peinado MA; Alonso J; de Alava E; Monk D; Esteller M; Tirado OM
    Cancer Lett; 2017 Feb; 386():196-207. PubMed ID: 27894957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
    Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
    Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
    Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
    González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
    Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
    Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
    Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.
    Pishas KI; Adwal A; Neuhaus SJ; Clayer MT; Farshid G; Staudacher AH; Callen DF
    Sci Rep; 2015 Jun; 5():11465. PubMed ID: 26095524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor.
    Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
    Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
    Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
    Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
    Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
    Loganathan SN; Tang N; Holler AE; Wang N; Wang J
    Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
    Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
    Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.